


Claims

1. (currently amended) The compound of claim 23, having the formula:



wherein

R¹ is a member selected from hydrogen, substituted or unsubstituted C₁-C₄ alkyl and substituted or unsubstituted C₃₋₆ cycloalkyl;


R² is a member selected from substituted or unsubstituted phenyl, substituted or unsubstituted benzyl and substituted or unsubstituted C₃-C₆ cycloalkyl;

R³ is a member selected from substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidyl, substituted or unsubstituted pyrazinyl, and phenyl substituted with a member selected from S(O)_nNR^{3a}R^{3b}, NR^{3a}S(O)_nR^{3b}, S(O)_nR^{3a}, NR^{3a}R^{3b}, ~~NR^{3a}C(O)R^{3b}~~; ~~OC(O)R^{3b}~~; OC(O)OR^{3b}, C(O)R^{3b}, and C(O)NR^{3a}R^{3b} and OR^{3a};

wherein R^{3a} and R^{3b} are members independently selected from H, substituted or unsubstituted C₁-C₆ alkyl and substituted or unsubstituted aryl; and

n is a member selected from 0, 1 and 2.

2. (currently amended) The compound according to claim 1 wherein R³ has a formula which is a member selected from:




3. (previously presented) The compound according to claim 1, wherein R^1 is a member selected from C_1 - C_3 haloalkyl and methyl.

4. (previously presented) The compound according to claim 1, wherein R^2 is cyclopentyl.

5-22. (canceled)

23. (currently amended) A compound having the formula:




wherein

R^{10} is a member selected from hydrogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkyloxy, C_{3-6} cycloalkyl-oxy, halo and cyano;

R^{11} is a member selected from substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidyl, substituted or unsubstituted C_{3-6} cycloalkyl, substituted or

unsubstituted phenyl, substituted or unsubstituted benzyl, and a group selected from (a) or (b):




wherein R^{13} , R^{14} , R^{15} , R^{16} , and R^{17} are members independently selected from hydrogen, halo, hydroxy, methyl, ethenyl, methoxy, ethoxy, nitro, trifluoromethyl, difluoromethyl, difluoromethoxy, trifluoroethoxy, trifluoromethoxy, OC_2H_5 , CH_2OH , $C(O)CH_3$, $S(O)_nCH_3$, $S(O)_nC_2H_5$ and cyano;

wherein n is 0, 1 or 2; ~~and~~

R^{12} is a member selected from substituted ~~or unsubstituted~~ aryl, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroaryl ~~and substituted or unsubstituted heteroarylalkyl~~.

wherein said substituted aryl is substituted with halo, methyl, ethenyl, amino, cyano, trifluoromethyl, CH_2OH , $S(O)_nNR^{3a}R^{3b}$, $NR^{3a}S(O)_nR^{3b}$, $S(O)_nR^{3a}$, $NR^{3a}R^{3b}$, $OC(O)OR^{3b}$, $C(O)R^{3b}$, $C(O)NR^{3a}R^{3b}$, $NH-C(=O)-NR^{3a}R^{3b}$, $C(=NH)-NH_2$, $NH-C(=S)-NHPh$, $C(O)NH-OH$, tetrazolyl,



R^{3a} and R^{3b} are members independently selected from H, substituted or unsubstituted C_1-C_6 alkyl and substituted or unsubstituted aryl.

24. (previously presented) The compound according to claim 23 in which at least one of R^{13} , R^{14} , R^{15} , R^{16} , and R^{17} is CN.


25. (previously presented) The compound according to claim 23 in which R^{13} is

halogen and R¹⁷ is CN.


26. (currently amended) The compound according to claim 23 in which R¹² is selected from substituted phenyl, substituted or unsubstituted ~~phenyl~~, benzyl, pyridinyl, quinolinyl, pyridazinyl, pyrazinyl, and pyrimidinyl.

27. (currently amended) The compound according to claim 26 in which said substitutions on said benzyl, pyridinyl, quinolinyl, pyridazinyl, pyrazinyl or pyrimidinyl include up to 2 members independently selected from halo, methyl, ethenyl, amino, nitro, cyano, trifluoromethyl, ethoxy-carbonyl, C(O)OH, C(O)OCH₃, S(O)₂NH₂, C(O)NH₂, C(O)NHC₂H₅, NHS(O)₂CH₃, CH₂OH, S(O)₂CH₃, SCH₃, and SC₂H₅.

28. (currently amended) The compound according to claim [[27]] 23, wherein said R¹² is substituted phenyl, and said substituted phenyl is a member selected from



29. (previously presented) The compound according to claim 28 wherein said compound is a member selected from:



30. (currently amended) The compound according to claim [[23]] 42 in which R¹⁰ is halogen;
 R¹¹ is a member selected from substituted pyridinyl, substituted pyrimidyl, and a group selected from (a) or (b):

R¹² is a member selected from substituted pyridinyl and substituted aryl.

[illegible]

R^{12} is a member selected from:


33. (previously presented) The compound according to claim 32 in which at least one of R¹³, R¹⁴, R¹⁵, R¹⁶, and R¹⁷ is CN.

34. (previously presented) The compound according to claim 32 in which R¹³ is halogen and R¹⁷ is CN.

35. (previously presented) The compound according to claim 32 in which R¹² is substituted or unsubstituted phenyl.

36. (previously presented) The compound according to claim 35 in which said substituted phenyl is substituted with a member selected from S(O)₂NH₂ and C(O)NH₂.

37. (previously presented) The compound according to claim 36 wherein said substituted phenyl is a member selected from:




38. (previously presented) A pharmaceutical composition comprising the compound of claim 23.

39. (withdrawn) A method of treating HIV infection in a human subject comprising administering to said subject the compound of claim 23 in an amount sufficient to treat said HIV infection.

40. (withdrawn) A method of inhibiting HIV replication in a cell, comprising contacting said cell with the compound of claim 23 in an amount sufficient to inhibit said HIV replication.

41. (withdrawn) A method of inhibiting reverse transcriptase in a cell, comprising contacting said cell with the compound of claim 23 in an amount sufficient to inhibit said reverse transcriptase.


42. (new) A compound having the formula:



wherein:

R¹⁰ is halogen;

R¹¹ is a member selected from substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrimidyl, substituted or unsubstituted C₃₋₆ cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, and a group selected from (a) or (b):



wherein R¹³, R¹⁴, R¹⁵, R¹⁶, and R¹⁷ are members independently selected from hydrogen, halo, hydroxy, methyl, ethenyl, methoxy, ethoxy, nitro, trifluoromethyl, difluoromethyl, difluoromethoxy, trifluoroethoxy, trifluoromethoxy, OC₂H₅, CH₂OH, C(O)CH₃, S(O)_nCH₃, S(O)_nC₂H₅ and cyano;

n is 0, 1 or 2; and

R¹² is a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl.

43. (new) A pharmaceutical composition comprising the compound of claim 42.

44. (new) A method of treating HIV infection in a human subject comprising administering to said subject the compound of claim 42 in an amount sufficient to treat said HIV infection.

45. (new) A method of inhibiting HIV replication in a cell, comprising contacting said cell with the compound of claim 42 in an amount sufficient to inhibit said HIV replication.

46. (new) A method of inhibiting reverse transcriptase in a cell, comprising contacting said cell with the compound of claim 42 in an amount sufficient to inhibit said reverse transcriptase.